 |
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to be acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Crinetics’ Palsonify medicine is the first and only once-daily oral therapy for a debilitating condition caused by a pituitary tumor that secretes excess growth hormone. It received approval from the FDA in September 2025 and was recently okayed by the European Medicines Agency.
Reshma Kewalramani, Vertex CEO, called Crinetics an excellent strategic fit “with its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines that could deliver transformative benefit to patients.”
She believes Vertex, which generated $12B in 2025 sales, can build on the strong momentum of the Palsonify launch by applying its experience in commercializing medicines for rare genetic diseases.
Joele Frank, Wilkinson Brimmer Katcher partners Jamie Moser and Jed Repko, and managing directors Catherine Simon and Fouad Boutros represent Crinetics.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
Joele Frank handles Minneapolis-based Bio-Techne, provider of life science tools and analytical technologies, as it gets acquired by Germany’s Merck KGaA in a deal valued at $11.3B.
